Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CDK2 | P24941 | 3/20 | 0.42 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.42 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.42 |
| ▸ | PRKACA | P17612 | 1/20 | 0.42 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.42 |
| ▸ | MARK3 | P27448 | 1/20 | 0.42 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.42 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.42 |
| ▸ | MARK2 | Q7KZI7 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | PI4KA | P42356 | 2/20 | 0.37 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.37 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21334364 | 0.82 | ALDH1A1 (0.41) | ALDH1A1CDK2PDPK1LRRK2CHEK1 | |
| SCHEMBL21335009 | 0.78 | ALDH1A1 (0.52) | ALDH1A1CDK2PDPK1LRRK2CHEK1 | |
| SCHEMBL10441259 | 0.77 | ALDH1A1 (0.38) | ALDH1A1CDK2PDPK1LRRK2CHEK1 | |
| SCHEMBL15367225 | 0.74 | ALDH1A1 (0.48) | ALDH1A1CDK2PDPK1LRRK2CHEK1 | |
| SCHEMBL16739940 | 0.74 | ALDH1A1 (0.48) | ALDH1A1CDK2PDPK1LRRK2CHEK1 | |
| SCHEMBL23790560 | 0.74 | ALDH1A1 (0.48) | ALDH1A1CDK2PDPK1LRRK2CHEK1 | |
| SCHEMBL10441257 | 0.73 | BRD4 (0.42) | ALDH1A1CDK2PDPK1LRRK2CHEK1 | |
| SCHEMBL23771325 | 0.72 | ALDH1A1 (0.50) | ALDH1A1CDK2PDPK1LRRK2CHEK1 | |
| SCHEMBL2563730 | 0.68 | ADORA3 (0.51) | ALDH1A1HSD17B10LMNASMN1; SMN2BRD4 | |
| SCHEMBL24995361 | 0.68 | CDK2 (0.41) | ALDH1A1CDK2PDPK1TP53XDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025922-A1 | TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS | MERCK HEALTHCARE KGAA (DE) | 2024-01-25 | — | — | US | disclosed |
| US-20240025922-A1 | TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS | MERCK HEALTHCARE KGAA (DE) | 2024-01-25 | — | — | US | disclosed |
| US-11566003-B2 | Isoquinolines as inhibitors of HPK1 | GENENTECH, INC. (US) | 2023-01-31 | — | — | US | disclosed |
| US-20210277024-A1 | NAPHTHYRIDINE COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2021-09-09 | — | — | US | disclosed |
| US-20210253580-A1 | ISOQUINOLINE COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2021-08-19 | — | — | US | disclosed |
| US-11034692-B1 | Naphthyridines as inhibitors of HPK1 | GENENTECH, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-20210163417-A1 | ISOQUINOLINES AS INHIBITORS OF HPK1 | GENENTECH, INC. (US) | 2021-06-03 | — | — | US | disclosed |
| WO-2020072695-A1 | 8-AMINOISOQUINOLINE COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2020-04-09 | — | — | WO | disclosed |
| WO-2020069402-A1 | CINNOLINE COMPOUNDS AND FOR THE TREATMENT OF HPK1-DEPENDENT DISORDERS SUCH AS CANCER | GENENTECH, INC. (US) | 2020-04-02 | — | — | WO | disclosed |
| WO-2020023551-A1 | NAPHTHYRIDINE COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2020-01-30 | — | — | WO | disclosed |
| US-10407424-B2 | Naphthyridines as inhibitors of HPK1 | GENENTECH, INC. (US) | 2019-09-10 | — | — | US | disclosed |
| EP-0517812-A4 | ANGIOTENSIN II ANTAGONISTS INCORPORATING A SUBSTITUTED BENZYL ELEMENT | MERCK & CO INC (US) | 1995-10-18 | — | — | EP | disclosed |
| US-5240938-A | Angiotensin II antagonists incorporating a substituted pyridoimidazolyl ring | MERCK & CO., INC. (US) | 1993-08-31 | — | — | US | disclosed |
| EP-0543491-A2 | Angiotensin II antagonists having a substituted 1,3-benzodioxolering or 1,3-benzodithiolering | MERCK & CO. INC. (US) | 1993-05-26 | — | — | EP | disclosed |
| EP-0517812-A1 | ANGIOTENSIN II ANTAGONISTS INCORPORATING A SUBSTITUTED BENZYL ELEMENT | MERCK & CO. INC. (US) | 1992-12-16 | — | — | EP | disclosed |
| WO-1991011999-A1 | ANGIOTENSIN II ANTAGONISTS INCORPORATING A SUBSTITUTED BENZYL ELEMENT | MERCK & CO., INC. (US) | 1991-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10407424-B2 | Naphthyridines as inhibitors of HPK1 | NEK1, NEK5, NEK11 | ALDH1A1 4630/4885CDK2 2997/4885PDPK1 75/4885 |
| US-20240025922-A1 | TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS | PDXK, DTYMK, HIPK1 | ALDH1A1 3576/4885CDK2 257/4885PDPK1 29/4885 |
| US-20210277024-A1 | NAPHTHYRIDINE COMPOUNDS AND USES THEREOF | NEK1, NEK11, NEK5 | ALDH1A1 3511/4885CDK2 1466/4885PDPK1 48/4885 |
| US-11034692-B1 | Naphthyridines as inhibitors of HPK1 | NEK1, NEK5, NEK11 | ALDH1A1 4630/4885CDK2 2997/4885PDPK1 75/4885 |
| US-20210253580-A1 | ISOQUINOLINE COMPOUNDS AND USES THEREOF | HIPK1, HPGDS, IP6K1 | ALDH1A1 3680/4885CDK2 913/4885PDPK1 35/4885 |
| US-11566003-B2 | Isoquinolines as inhibitors of HPK1 | HIPK1, HIPK2, IP6K1 | ALDH1A1 4451/4885CDK2 1223/4885PDPK1 42/4885 |
| US-20210163417-A1 | ISOQUINOLINES AS INHIBITORS OF HPK1 | HIPK1, HIPK2, IP6K1 | ALDH1A1 4451/4885CDK2 1223/4885PDPK1 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.